Aptitude is hiring! See current openings.
Aptitude demonstrated the in vivo efficacy of two aptamer therapeutic programs
Aptitude has received 5 million dollars in non-dilutive funding
Aptitude started collaboration with a global leader in clinical diagnostics
Imagine a synthetic antibody that:
is highly stable, resistant to denaturing, and works with diverse platforms, from mainstream assays to cutting-edge electrochemical sensors
binds with high affinity and specificity to intractable targets, and discriminates targets that differ by only a single functional group
accommodates various functional modifications, and seamlessly integrates with powerful qPCR and next-gen sequencing detection
Imagine a company who can turn that dream into reality.
Welcome to the reality of Aptitude.
Find out who is behind the Aptitude technology